Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Fenchel

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Translational Lung Cancer Research|November 10, 2016
Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?Wolfram C M Dempke, Klaus Fenchel
Translational Lung Cancer Research|May 22, 2018
Durvalumab for non-resectable stage IIIB non-small cell lung cancer-a small step or a big leap?Wolfram C M Dempke, Klaus Fenchel
Signal Transduction and Targeted Therapy|January 5, 2025
TET2 cascade: a novel regulator of chromatin structure and leukaemogenesisWolfram C M Dempke, Klaus Fenchel
Translational Lung Cancer Research|January 5, 2018
Treating epidermal growth factor receptor-mutated non-small cell lung cancer-is dacomitinib the winner?Wolfram C M Dempke, Klaus Fenchel
Translational Cancer Research|December 19, 2024
Targeting C797S mutations and beyond in non-small cell lung cancer-a mini-reviewWolfram C M Dempke, Klaus Fenchel
Translational Lung Cancer Research|July 23, 2021
Has programmed cell death ligand-1 <i>MET</i> an accomplice in non-small cell lung cancer?-a narrative reviewWolfram C M Dempke, Klaus Fenchel
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 29, 2017
Michael Max Sachse, Klaus Fenchel, Gunnar Wagner
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 2, 2014
Regression of B-RAF inhibitor associated keratoacanthomas by acitretin - how do retinoids act on the RAF/MEK/ERK-signaling pathway?Michael Max Sachse, Klaus Fenchel, Gunnar Wagner
Cancers|January 28, 2026
Zipalertinib-A Novel Treatment Opportunity for Non-Small Cell Lung Cancers with Exon 20 Insertions and Uncommon EGFR MutationsWolfram C M Dempke, Klaus Fenchel, Niels Reinmuth
Translational Lung Cancer Research|March 10, 2016
Overall survival in non-small cell lung cancer-what is clinically meaningful?Klaus Fenchel, Ludger Sellmann, Wolfram C M Dempke
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Translational Lung Cancer Research|November 10, 2016
Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?Wolfram C M Dempke, Klaus Fenchel
Translational Lung Cancer Research|May 22, 2018
Durvalumab for non-resectable stage IIIB non-small cell lung cancer-a small step or a big leap?Wolfram C M Dempke, Klaus Fenchel
Signal Transduction and Targeted Therapy|January 5, 2025
TET2 cascade: a novel regulator of chromatin structure and leukaemogenesisWolfram C M Dempke, Klaus Fenchel
Translational Lung Cancer Research|January 5, 2018
Treating epidermal growth factor receptor-mutated non-small cell lung cancer-is dacomitinib the winner?Wolfram C M Dempke, Klaus Fenchel
Translational Cancer Research|December 19, 2024
Targeting C797S mutations and beyond in non-small cell lung cancer-a mini-reviewWolfram C M Dempke, Klaus Fenchel
Translational Lung Cancer Research|July 23, 2021
Has programmed cell death ligand-1 <i>MET</i> an accomplice in non-small cell lung cancer?-a narrative reviewWolfram C M Dempke, Klaus Fenchel
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 29, 2017
Michael Max Sachse, Klaus Fenchel, Gunnar Wagner
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 2, 2014
Regression of B-RAF inhibitor associated keratoacanthomas by acitretin - how do retinoids act on the RAF/MEK/ERK-signaling pathway?Michael Max Sachse, Klaus Fenchel, Gunnar Wagner
Cancers|January 28, 2026
Zipalertinib-A Novel Treatment Opportunity for Non-Small Cell Lung Cancers with Exon 20 Insertions and Uncommon EGFR MutationsWolfram C M Dempke, Klaus Fenchel, Niels Reinmuth
Translational Lung Cancer Research|March 10, 2016
Overall survival in non-small cell lung cancer-what is clinically meaningful?Klaus Fenchel, Ludger Sellmann, Wolfram C M Dempke
Pageof 3